Drug Trial Radar · NCT06517693
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jan 5, 2026
Primary completion
Nov 30, 2027
Study completion May 31, 2029
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 72 hours
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.
Conditions
- HIV-1
Interventions
PGT121.414.LSDrug
Administered SC in the thigh
VRC07-523LSDrug
Administered SC in the thigh
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of infants with at least one Grade 3 or higher Adverse Event (AE) (one dose)Time frame: Day 0 through Week 12
- Proportion of infants with at least one Grade 3 or higher AE assessed as related to study product (one dose)Time frame: Day 0 through Week 12
- Proportion of infants with at least one Grade 3 or higher AE (two doses)Time frame: Day 0 through Week 24
- Proportion of infants with at least one Grade 3 or higher AE assessed as related to study product (two doses)Time frame: Day 0 through Week 24
- PGT121.414.LS maximum concentration (Cmax) (single/first dose)Time frame: Day 0 through Week 48
- PGT121.414.LS time of maximum concentration (Tmax) (single/first dose)Time frame: Day 0 through Week 48
- PGT121.414.LS area under the curve (AUC(0-12WK)) (single/first dose)Time frame: Day 0 through Week 12
- PGT121.414.LS concentration at the end of the first dose interval (C(12WK)) (single/first dose)Time frame: Week 12
- PGT121.414.LS concentration at the end of the second dose interval (C(24WK)) (two doses)Time frame: Week 24
- VRC07-523LS maximum concentration (Cmax) (single/first dose)Time frame: Day 0 through Week 48
- VRC07-523LS time of maximum concentration (Tmax) (single/first dose)Time frame: Day 0 through Week 48
- VRC07-523LS area under the curve (AUC(0-12WK))Time frame: Day 0 through Week 12
- VRC07-523LS concentration at the end of the first dose interval (C(12WK)) single/first dose)Time frame: Week 12
- VRC07-523LS concentration at the end of the second dose interval (C(24WK)) (two doses)Time frame: Week 24
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
Site 5112, David Geffen School of Medicine at UCLA
Los Angeles, California · Not yet recruiting
Site 5052, University of Colorado Denver NICHD CRS
Aurora, Colorado · Recruiting
Site 5051, University of Florida Jacksonville NICHD CRS
Jacksonville, Florida · Recruiting
Site 32512, Pediatric Perinatal HIV CRS
Miami, Florida · Not yet recruiting
Site 5127, Pediatric Perinatal HIV
Miami, Florida · Withdrawn
Site 5030, Emory University School of Medicine NICHD CRS
Atlanta, Georgia · Not yet recruiting
Site 32515, Rush Univ./Cook County Hosp. Chicago CRS
Chicago, Illinois · Not yet recruiting
Site 5083, Rush University Cook County Hospital Chicago
Chicago, Illinois · Withdrawn
Site 5092, Johns Hopkins University Baltimore
Baltimore, Maryland · Recruiting
Site 5114, Bronx-Lebanon Hospital Center
The Bronx, New York · Recruiting
Site 5013, Jacobi Med. Ctr Bronx NICHD CRS
The Bronx, New York · Not yet recruiting
Site 6501, St. Jude Children's Research Hospital CRS
Memphis, Tennessee · Not yet recruiting
Site 5128, Baylor College of Medicine/Texas Children's Hospital NICHD CRS
Houston, Texas · Recruiting
Site 5097, Hospital Geral De Nova Iguacu Brazil NICHD CRS
Rio de Janeiro, Brazil · Not yet recruiting
Site 5072, Hospital Federal dos Servidores do Estado
Rio de Janeiro, Brazil, Brazil · Withdrawn
Site 5121, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho CRS
Kericho, Kenya · Recruiting
Site 32513, IMPAACT/Gamma Project/UPR Pediatric HIV/AIDS Research Network CRS
San Juan, Puerto Rico, Puerto Rico · Not yet recruiting
Site 8950, FAMCRU
Cape Town, Parrow Valley, South Africa · Not yet recruiting
Site 31890, Harare Family Care CRS
Harare, Zimbabwe · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.